Predicting the Long-Term Outcomes of Biologics in Psoriasis Patients Using Machine Learning
Sepideh Emam, Amy X. Du, Philip Surmanowicz, Simon F. Thomsen, Russ, Greiner, Robert Gniadecki

TL;DR
This study demonstrates that machine learning models can accurately predict long-term biologic treatment outcomes in psoriasis patients, aiding personalized treatment decisions and guideline development.
Contribution
The paper introduces machine learning models that predict biologic therapy discontinuation and duration in psoriasis with high accuracy, using a small set of predictive variables.
Findings
Predictive accuracy of 82% for drug discontinuation risk.
Identified patient profile with highest chances of success.
Mean absolute error of 4.5 months in treatment duration prediction.
Abstract
Background. Real-world data show that approximately 50% of psoriasis patients treated with a biologic agent will discontinue the drug because of loss of efficacy. History of previous therapy with another biologic, female sex and obesity were identified as predictors of drug discontinuations, but their individual predictive value is low. Objectives. To determine whether machine learning algorithms can produce models that can accurately predict outcomes of biologic therapy in psoriasis on individual patient level. Results. All tested machine learning algorithms could accurately predict the risk of drug discontinuation and its cause (e.g. lack of efficacy vs adverse event). The learned generalized linear model achieved diagnostic accuracy of 82%, requiring under 2 seconds per patient using the psoriasis patients dataset. Input optimization analysis established a profile of a patient who…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
